Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares at an average price of $531.38, generating approximately $5.05 million. Her remaining stake totals 324,443 shares, valued at about $172.4 million.
- The company reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus rating with an average price target of $646, while institutional investors own approximately 94.1% of United Therapeutics’ shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $531.38, for a total transaction of $5,048,110.00. Following the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at $172,402,521.34. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Stock Performance
United Therapeutics stock opened at $529.66 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $292.34 and a fifty-two week high of $609.35. The stock has a market cap of $22.72 billion, a P/E ratio of 18.95, a PEG ratio of 1.82 and a beta of 0.59. The firm's fifty day moving average price is $539.13 and its 200-day moving average price is $535.14.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm's revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.32 earnings per share for the current year.
Institutional Trading of United Therapeutics
A number of hedge funds have recently bought and sold shares of the company. Arjuna Capital grew its holdings in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC lifted its stake in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its stake in United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after buying an additional 26 shares during the period. Finally, Independent Advisor Alliance boosted its position in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after buying an additional 27 shares during the period. Institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
UTHR has been the topic of several research analyst reports. Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, July 31st. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $646.00.
Read Our Latest Stock Analysis on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
